OncoMatch/Clinical Trials/NCT04677413
Ultra-fractionated Radiotherapy for Rectal Cancer
Is NCT04677413 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for rectal cancer.
The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with chemotherapy. We believe delivering short course radiotherapy over a prolonged interval, at escalated doses and with concurrent chemotherapy may be feasible and allow for improved clinical response.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
wbc ≥ 3,000/ml; anc wbc ≥ 1,000/ml; plt ≥ 75,000/ml
Kidney function
creatinine not above uln, or creatinine clearance >50 ml/min/1.73 m^2 for participants with creatinine levels above institutional normal
Liver function
t bili ≤ 1.5 x uln; ast/alt ≤ 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04677413 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages